274 related articles for article (PubMed ID: 29472926)
1. Eliminating Factor H-Binding Activity of
Marcinkiewicz AL; Lieknina I; Kotelovica S; Yang X; Kraiczy P; Pal U; Lin YP; Tars K
Front Immunol; 2018; 9():181. PubMed ID: 29472926
[TBL] [Abstract][Full Text] [Related]
2. The Factor H-Binding Site of CspZ as a Protective Target against Multistrain, Tick-Transmitted Lyme Disease.
Marcinkiewicz AL; Lieknina I; Yang X; Lederman PL; Hart TM; Yates J; Chen WH; Bottazzi ME; Mantis NJ; Kraiczy P; Pal U; Tars K; Lin YP
Infect Immun; 2020 Apr; 88(5):. PubMed ID: 32122944
[TBL] [Abstract][Full Text] [Related]
3. Blood treatment of Lyme borreliae demonstrates the mechanism of CspZ-mediated complement evasion to promote systemic infection in vertebrate hosts.
Marcinkiewicz AL; Dupuis AP; Zamba-Campero M; Nowak N; Kraiczy P; Ram S; Kramer LD; Lin YP
Cell Microbiol; 2019 Feb; 21(2):e12998. PubMed ID: 30571845
[TBL] [Abstract][Full Text] [Related]
4. CspZ FH-Binding Sites as Epitopes Promote Antibody-Mediated Lyme Borreliae Clearance.
Chen YL; Marcinkiewicz AL; Nowak TA; Tyagi Kundu R; Liu Z; Strych U; Bottazzi ME; Chen WH; Lin YP
Infect Immun; 2022 Jul; 90(7):e0006222. PubMed ID: 35861564
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of the properties and ligand binding characteristics of CspZ, a factor H binding protein, derived from Borrelia burgdorferi isolates of human origin.
Rogers EA; Abdunnur SV; McDowell JV; Marconi RT
Infect Immun; 2009 Oct; 77(10):4396-405. PubMed ID: 19620346
[TBL] [Abstract][Full Text] [Related]
6. Delineation of species-specific binding properties of the CspZ protein (BBH06) of Lyme disease spirochetes: evidence for new contributions to the pathogenesis of Borrelia spp.
Rogers EA; Marconi RT
Infect Immun; 2007 Nov; 75(11):5272-81. PubMed ID: 17846117
[TBL] [Abstract][Full Text] [Related]
7. Borrelia burgdorferi BBA52 is a potential target for transmission blocking Lyme disease vaccine.
Kumar M; Kaur S; Kariu T; Yang X; Bossis I; Anderson JF; Pal U
Vaccine; 2011 Nov; 29(48):9012-9. PubMed ID: 21945261
[TBL] [Abstract][Full Text] [Related]
8. Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs.
Scheckelhoff MR; Telford SR; Hu LT
Vaccine; 2006 Mar; 24(11):1949-57. PubMed ID: 16300863
[TBL] [Abstract][Full Text] [Related]
9. Identification of Surface Epitopes Associated with Protection against Highly Immune-Evasive VlsE-Expressing Lyme Disease Spirochetes.
Batool M; Caoili SEC; Dangott LJ; Gerasimov E; Ionov Y; Piontkivska H; Zelikovsky A; Waghela SD; Rogovskyy AS
Infect Immun; 2018 Aug; 86(8):. PubMed ID: 29866906
[TBL] [Abstract][Full Text] [Related]
10. Structural evolution of an immune evasion determinant shapes pathogen host tropism.
Marcinkiewicz AL; Brangulis K; Dupuis AP; Hart TM; Zamba-Campero M; Nowak TA; Stout JL; Akopjana I; Kazaks A; Bogans J; Ciota AT; Kraiczy P; Kolokotronis SO; Lin YP
Proc Natl Acad Sci U S A; 2023 Jul; 120(27):e2301549120. PubMed ID: 37364114
[TBL] [Abstract][Full Text] [Related]
11. The OspE-related proteins inhibit complement deposition and enhance serum resistance of Borrelia burgdorferi, the lyme disease spirochete.
Kenedy MR; Akins DR
Infect Immun; 2011 Apr; 79(4):1451-7. PubMed ID: 21282413
[TBL] [Abstract][Full Text] [Related]
12. Characterization of recombinant OspA in two different Borrelia vaccines with respect to immunological response and its relationship to functional parameters.
Grosenbaugh DA; De Luca K; Durand PY; Feilmeier B; DeWitt K; Sigoillot-Claude C; Sajous ML; Day MJ; David F
BMC Vet Res; 2018 Oct; 14(1):312. PubMed ID: 30326885
[TBL] [Abstract][Full Text] [Related]
13. Complement evasion strategies of Borrelia burgdorferi sensu lato.
Dulipati V; Meri S; Panelius J
FEBS Lett; 2020 Aug; 594(16):2645-2656. PubMed ID: 32748966
[TBL] [Abstract][Full Text] [Related]
14. Structural characterization of CspZ, a complement regulator factor H and FHL-1 binding protein from Borrelia burgdorferi.
Brangulis K; Petrovskis I; Kazaks A; Bogans J; Otikovs M; Jaudzems K; Ranka R; Tars K
FEBS J; 2014 Jun; 281(11):2613-22. PubMed ID: 24702793
[TBL] [Abstract][Full Text] [Related]
15. Specific immune response to a synthetic peptide derived from outer surface protein C of Borrelia burgdorferi predicts protective borreliacidal antibodies.
Ikushima M; Matsui K; Yamada F; Kawahashi S; Nishikawa SK
FEMS Immunol Med Microbiol; 2000 Sep; 29(1):15-21. PubMed ID: 10967255
[TBL] [Abstract][Full Text] [Related]
16. Borrelia burgdorferi BBI39 Paralogs, Targets of Protective Immunity, Reduce Pathogen Persistence Either in Hosts or in the Vector.
Singh P; Verma D; Backstedt BT; Kaur S; Kumar M; Smith AA; Sharma K; Yang X; Azevedo JF; Gomes-Solecki M; Buyuktanir O; Pal U
J Infect Dis; 2017 Mar; 215(6):1000-1009. PubMed ID: 28453837
[TBL] [Abstract][Full Text] [Related]
17. Functional characterization of BbCRASP-2, a distinct outer membrane protein of Borrelia burgdorferi that binds host complement regulators factor H and FHL-1.
Hartmann K; Corvey C; Skerka C; Kirschfink M; Karas M; Brade V; Miller JC; Stevenson B; Wallich R; Zipfel PF; Kraiczy P
Mol Microbiol; 2006 Sep; 61(5):1220-36. PubMed ID: 16925556
[TBL] [Abstract][Full Text] [Related]
18. A new approach to a Lyme disease vaccine.
Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ
Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA.
Koide S; Yang X; Huang X; Dunn JJ; Luft BJ
J Mol Biol; 2005 Jul; 350(2):290-9. PubMed ID: 15935380
[TBL] [Abstract][Full Text] [Related]
20. Biophysical and biochemical characterization of a recombinant Lyme disease vaccine antigen, CspZ-YA.
Chen YL; Lee J; Liu Z; Strych U; Bottazzi ME; Lin YP; Chen WH
Int J Biol Macromol; 2024 Feb; 259(Pt 2):129295. PubMed ID: 38211914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
